Pro-apoptotic components of the same family, namely BAX and BAK, are concomitantly less expressed [13,74], making this protein family an attractive therapeutic target for the treatment of CLL [78]. This evidence concerns the gene BAK1 and B-cell chronic lymphocytic leukemia.